Slide One
Slide Two
Slide Three

Charleston Gazette
November 6, 2013
by Caitlin Cook
Business editor

Charleston, W.Va. -- West Virginia entrepreneurs and business owners may have a new way to find investors, with a new program announced by state and regional officials Wednesday.

In advance of a regional economic conference Thursday, the Appalachian Regional Commission announced its West Virginia "angel" investment fund Wednesday afternoon.
The fund will try to help businesses that can't find funding or access to business resources, but have the potential to benefit the community.

Tom Heywood, vice chairman of the West Virginia Growth Fund, said "angel investments" are known in the investment world as feel-good investments. Heywood likened the angel investment to lending to a friend or family member.

Doctors Pier Claudio and Jagan Valluri have been working for years on a chemo sensitivity test, called ChemoID. They take a biopsy of a tumor, multiply the cancer stem cells, and find out what type of chemo that particular cancer will respond best to.

"I think you know the whole goal of cancer, is you know we want to cure it, but more importantly, how can we prolong the life of a cancer patient?" Valluri said.

Groundbreaking cancer research going on right here in Huntington could soon change the way patients are treated. 

"This is definitely a cutting edge technology for the 21st century for cancer patients," said Dr. Pier Paolo Claudio, a biomedical sciences researcher and professor at Marshall University's Joan C. Edwards School of Medicine. 


The 3rd Annual West Virginia Bioscience Summit, with sponsorship from BIO, PhRMA, Mylan, Amgen, Pfizer, the Blanchette Rockefeller Neuroscience Institute, the WV Small Business Development Center, Steptoe & Johnson PLLC, Fisher Scientific and TechConnect West Virginia, was held February 27-28, 2013 at the Charleston Marriott in Charleston, West Virginia.
This unique event drew together the region’s bioscience industry, to include university researchers, biotechnology company representatives, economic developers, funders, industry vendors, resource organizations and many others.  The Summit highlighted the role and impact of the bioscience industry in West Virginia and the region, showcased research and commercialization efforts taking place at West Virginia universities and private companies, and discussed policies and programs to help nurture the industry.
To review the event agenda, click here.
To review presentations offered during the event, click here.
To review a partial list of event attendees, click here.
To read media reports of the event from the Charleston Gazette click here, or for The State Journal, click here.
The dates for the 4th Annual WV Bioscience Summit – to be held winter 2014 – will be announced in the coming months.
For additional information, email This email address is being protected from spambots. You need JavaScript enabled to view it.

By Megan Workman
Charleston Gazette

CHARLESTON, W.Va. -- If David Scholl had given up on the Athens, Ohio-based startup biotech company that launched in the early 1980s, the company might not have sold for $130 million three years ago.

Scholl, the former president and chief executive officer of Diagnostic Hybrids Inc., spoke to a group of about 100 representatives from private companies, university researchers and biosciences suppliers and backers at the third annual West Virginia Biosciences Summit Thursday at the Charleston Marriott Town Center.

PO BOX 20065 | Charleston, WV 25362 | (304) 546-5500